ADiTx Therapeutics Inc. [NASDAQ: ADTX] stock went on an upward path that rose over 0.96% on Monday, amounting to a one-week price decrease of less than -6.67%. The company report on December 14, 2020 that Aditxt Signs Distribution Agreement with Todos Medical Ltd. For AditxtScore™ for COVID-19 Immune Monitoring Service.
Service Availability is Expected in January 2021.
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
via NewMediaWire – Aditx Therapeutics, Inc. (Aditxt) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, and Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for early detection of cancer and Alzheimer’s disease, announced the signing of a distribution agreement for AditxtScore™ for COVID-19, with planned availability in January 2021.
The market cap for the stock reached $26.54 million, with 12.28 million shares outstanding and 9.25 million shares in the current float. Compared to the average trading volume of 1.12M shares, ADTX stock reached a trading volume of 432658 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on ADiTx Therapeutics Inc. [ADTX]:
The Average True Range (ATR) for ADiTx Therapeutics Inc. is set at 0.16 The Price to Book ratio for the last quarter was 1.14, with the Price to Cash per share for the same quarter was set at 1.08.
ADTX Stock Performance Analysis:
ADiTx Therapeutics Inc. [ADTX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.67. With this latest performance, ADTX shares gained by 7.14% in over the last four-week period, additionally sinking by -43.24% over the last 6 months.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ADTX stock in for the last two-week period is set at 50.10, with the RSI for the last a single of trading hit 48.19, and the three-weeks RSI is set at 49.78 for ADiTx Therapeutics Inc. [ADTX]. The present Moving Average for the last 50 days of trading for this stock 2.04, while it was recorded at 2.14 for the last single week of trading.
Insight into ADiTx Therapeutics Inc. Fundamentals:
Reflecting on the efficiency of the workforce at the company, ADiTx Therapeutics Inc. [ADTX] managed to generate an average of -$2,913,864 per employee.ADiTx Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 18.90 and a Current Ratio set at 18.90.
ADiTx Therapeutics Inc. [ADTX] Insider Position Details
There are presently around $1 million, or 7.10% of ADTX stock, in the hands of institutional investors. The top three institutional holders of ADTX stocks are: SABBY MANAGEMENT, LLC with ownership of 224,971, which is approximately New of the company’s market cap and around 4.50% of the total institutional ownership; WEDBUSH SECURITIES INC, holding 61,832 shares of the stock with an approximate value of $0.13 million in ADTX stocks shares; and POWELL INVESTMENT ADVISORS, LLC, currently with $80000.0 in ADTX stock with ownership of nearly New of the company’s market capitalization.
9 institutional holders increased their position in ADiTx Therapeutics Inc. [NASDAQ:ADTX] by around 358,221 shares. Additionally, 2 investors decreased positions by around 110,461 shares, while 0 investors held positions by with 110,461 shares. The mentioned changes placed institutional holdings at 358,221 shares, according to the latest SEC report filing. ADTX stock had 9 new institutional investments in for a total of 358,221 shares, while 2 institutional investors sold positions of 110,461 shares during the same period.